Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colon Diseases Clear all
Completed Not applicable Interventional

RCT of VR Therapy for IBS

NCT06687616
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
SynerGI, Sham VR
Device
Lead sponsor
Christopher Almario
Other
Eligibility
10 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 22, 2026, 7:23 AM EDT
Recruiting No phase listed Observational

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

NCT00899626
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Precancerous Condition
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2045
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening

NCT03414125
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FIT Screening Strategy, Choice Screening Strategy
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 63 Years
Enrollment
26,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 22, 2026, 7:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633
View directory record Official record
Conditions
Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
[18F]FPyQCP
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

NCT04166435
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Temozolomide + Olaparib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Phase 1 Interventional

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

NCT00026364
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, gefitinib, irinotecan hydrochloride, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 22, 2026, 7:23 AM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00492999
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06720987
View directory record Official record
Conditions
KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
Interventions
KQB365, Cetuximab, KQB198
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women

NCT00376909
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions
educational intervention, study of socioeconomic and demographic variables
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
2,729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Satisfaction With Propofol for Out Patient Colonoscopy

NCT02937506
View directory record Official record
Conditions
Colon Cancer, IBS, Polyps
Interventions
Propofol, Fentanyl Plus Midazolam
Drug
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 22, 2026, 7:23 AM EDT
Terminated Phase 3 Interventional Results available

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

NCT01011478
View directory record Official record
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
rosuvastatin, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
584
States / cities
Anniston, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 423 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 22, 2026, 7:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Upadacitinib (ABT-494), Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
147
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Not listed Not applicable Interventional

Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis

NCT05662059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RAVANS, RAVANS-sham
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
10 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 22, 2026, 7:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NCT05784688
View directory record Official record
Conditions
Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
TU2218 + KEYTRUDA® (Pembrolizumab)
Drug
Lead sponsor
TiumBio Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
San Antonio, Texas • Tyler, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 22, 2026, 7:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Contribution of Pain and Inflammation in IBS

NCT01436760
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 22, 2026, 7:23 AM EDT
Active, not recruiting No phase listed Observational Results available

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

NCT03516942
View directory record Official record
Conditions
Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Colon Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Colon Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
716
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 438 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
TSN1611
Drug
Lead sponsor
Tyligand Pharmaceuticals (Suzhou) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening

NCT01773980
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions
Clinic Intervention, Patient Intervention
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
1,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 22, 2026, 7:23 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

NCT01239082
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy, Fecal immunochemical test (FIT)
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
50,126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 22, 2026, 7:23 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NCT01960023
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Cetuximab, Neratinib
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Gainesville, Florida • Orlando, Florida • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 22, 2026, 7:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Comparision of Air Versus CO2 for Distention During Sigmoidoscopy

NCT00771290
View directory record Official record
Conditions
Colorectal Surgery
Interventions
Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 22, 2026, 7:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 22, 2026, 7:23 AM EDT